Keywords: AstraZeneca, Brilinta, Meck KGaA, Cladribine, Movectro, Blood thinner, Multiple sclerosis

Regulatory updates: AstraZeneca’s Brilinta; Merck KGaA’ cladribine

Article | 21 January 2011

Print This

European drug majors Anglo-Swedish AstraZeneca (LSE: AZN) and Germany’s Merck & Co (MRK: DE) gave updates this morning ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in